Cabozantinib versus everolimus in advanced renal cell carcinoma

BACKGROUND: Cabozantinib is an oral small molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL; each has been implicated in metastatic renal cell carcinoma (RCC) pathobiology or development of resistance to antiangiogenic drugs. T...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:N Engl J Med
Egile Nagusiak: Choueiri, Toni K., Escudier, Bernard, Powles, Thomas, Mainwaring, Paul, Rini, Brian I., Donskov, Frede, Hammers, Hans, Hutson, Thomas E., Lee, Jae-Lyun, Peltola, Katriina, Roth, Bruce J., Bjarnason, Georg A., Géczi, Lajos, Keam, Bhumsuk, Moroto, Pablo, Heng, Daniel Y. C., Schmidinger, Manuela, Kantoff, Philip W., Borgman, Anne, Hessel, Colin, Scheffold, Christian, Schwab, Gisela M., Tannir, Nizar M., Motzer, Robert J.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5024539/
https://ncbi.nlm.nih.gov/pubmed/26406150
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1510016
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak